- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 25.09. | Lilly's oral SERD gets FDA nod in advanced breast cancer | ||
| 25.09. | Lilly stops trial of muscle-sparing obesity drug | ||
| 25.09. | Capricor readies revised FDA pitch for Duchenne cell therapy | ||
| 25.09. | Cancer patients are living longer than ever. Pain drugmakers haven't kept up. | ||
| 24.09. | UniQure to seek approval of Huntington's gene therapy after trial win | ||
| 24.09. | Acadia to scrap Prader-Willi drug after study setback | ||
| 24.09. | Sanofi Ventures banks $625M to back young biotechs, digital health startups | ||
| 23.09. | Disparity in vaccine access between states roils patients, providers | ||
| 23.09. | Bristol Myers says next-gen blood cancer drug hits goal in key study | ||
| 23.09. | FDA, in unusual step, aims to repurpose old GSK drug as autism treatment | ||
| 23.09. | Scholar Rock SMA drug rejected by FDA over manufacturing concerns | ||
| 23.09. | FDA clears under-the-skin Keytruda; MBX shares double on study data | ||
| 23.09. | Why Xoma, a drug royalty firm, is hunting biotech 'zombies' | ||
| 22.09. | MapLight lines up an IPO in bid to challenge Bristol Myers schizophrenia drug | ||
| 22.09. | Pfizer buys back into obesity drug chase with $4.9B Metsera deal | ||
| 22.09. | FDA clears first Barth syndrome drug amid scrutiny of rare disease stance | ||
| 22.09. | Setting cell and gene therapies up for success with a smarter CMC strategy | ||
| 22.09. | Meet the new EmVenio - where science meets people | ||
| 19.09. | CDC panel, recast by RFK Jr., softens COVID vaccine recommendations | ||
| 19.09. | Arvinas reboots, cuts more staff; Porges joins Lazard | ||
| 19.09. | CDC advisers postpone vote to delay some newborns' hepatitis B shot | ||
| 18.09. | CDC panel recommends splitting measles, varicella shots | ||
| 18.09. | A new biotech venture firm emerges, led by Bob Langer's son | ||
| 18.09. | Biogen to buy startup Alcyone, eyeing easier delivery of RNA drugs | ||
| 18.09. | Roche dives into MASH with $2.4B deal for 89bio |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .